VEGFA and wet macular degeneration: Therefore, using intravitreal anti-VEGF monotherapy as the active-control group appears appropriate, considering the methodological desire to compare to a licensed and established standard of care for wet AMD, and an ethical imperative to avoid a control group with an anticipated poor outcome (natural history).